Memantine And Donepezil Capsule, Extended Release
Product Images NDC 33342-312

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Memantine And Donepezil (NDC 33342-312). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1111 (Memantine Donepezil Er 14 10mg 30s Bottle)

Label for Memantine and Donepezil Hydrochlorides Extended-release Capsules 14 mg/10 mg, showing a 30-capsule package. The label lists the active ingredients with strengths, manufacturer Macleods Pharmaceuticals Limited, and includes dosage instructions and storage conditions. The label features the Macleods Pharma USA logo and barcodes.*

FDA Label Image

2222 (Memantine Donepezil Er 14 10mg 90s Bottle)

The packaging label for Memantine and Donepezil Hydrochlorides Extended-release Capsules shows a dosage strength of 14 mg memantine and 10 mg donepezil. It includes manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd, along with storage instructions and usual dosage guidance. The label also indicates a quantity of 90 capsules and features multiple barcodes.*

FDA Label Image

3333 (Memantine Donepezil Er 14 mg 10 mg 100s)

Packaging label for Memantine and Donepezil Hydrochlorides Extended-release Capsules 14 mg/10 mg by Macleods Pharmaceuticals Limited. The label indicates a unit-dose carton containing 100 capsules (10 x 10). Manufacturer information includes Macleods Pharma USA, Inc., Princeton, NJ, and Macleods Pharmaceuticals Ltd., India. The label includes storage instructions, dosage form as extended-release capsules, and barcode.*

FDA Label Image

6666 (Memantine Donepezil Er 28 10mg 140s Carton)

Packaging label for Memantine and Donepezil Hydrochlorides Extended-Release Capsules, 28 mg/10 mg strength. The label states a count of 140 capsules (10 x 14) in unit-dose packaging. Manufactured by Macleods Pharmaceuticals Limited and Macleods Pharma USA, Inc. Instructions include storage conditions, usual dosage guidance, and barcode information. Capsules are oral extended-release formulation.*

FDA Label Image

4444 (Memantine Donepezil Er 28 10mg 30s Bottle)

Memantine and Donepezil Hydrochlorides Extended-release Capsules, 28 mg/10 mg, label from Macleods Pharmaceuticals Limited. The package contains 30 capsules. The label details the active ingredients and strengths, manufacturer information including Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., and storage instructions.*

FDA Label Image

5555 (Memantine Donepezil Er 28 mg 10 mg 90s)

Label for Memantine and Donepezil Hydrochlorides Extended-release Capsules, strength 28 mg/10 mg, in a package of 90 capsules. The label includes manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. It displays storage instructions and dosage guidance, along with barcodes and an area marked OPZ AREA.*

FDA Label Image

Str (Memantine Donepezil Er Donepezil Structure)

Chemical structure diagram of Memantine and Donepezil, showing molecular connectivity including benzene rings, piperidine ring, and functional groups, labeled with hydrochloride (HCl).*

FDA Label Image

Fig-1 (Memantine Donepezil Er Fig 1)

A line graph comparing mean changes from baseline in SIB scores over 24 weeks of treatment between Memantine HCl ER 28 mg/AChEI and placebo/AChEI groups. The x-axis shows weeks of treatment, and the y-axis shows mean change in score. Two lines with error bars illustrate clinical improvement or decline trends over time for both groups.*

FDA Label Image

Fig-2 (Memantine Donepezil Er Fig 2)

A cumulative percentage graph showing patient responses to Memantine HCl ER 28 mg/ACHEI compared to placebo/ACHEI. The x-axis represents SIB (Severe Impairment Battery) change from baseline, while the y-axis shows the cumulative percentage of patients. The graph illustrates the distribution of changes in patient scores over time for both groups.*

FDA Label Image

Fig-3 (Memantine Donepezil Er Fig 3)

A line graph depicting the mean CIBC/ADL scores over 24 weeks of treatment comparing Memantine HCl ER 28 mg/ACheI to placebo/ACheI. The y-axis measures mean scores with clinical improvement and decline indicated; the x-axis shows weeks of treatment.*

FDA Label Image

Fig-4 (Memantine Donepezil Er Fig 4)

A bar chart comparing the percentage of patients by CIBIC-Plus Rating categories for Memantine HCl ER 28 mg/AChEI versus Placebo/AChEI groups. The rating categories range from marked improvement to marked worsening, with data showing distribution percentages for each treatment group across these categories.*

FDA Label Image

Fig-5 (Memantine Donepezil Er Fig 5)

A line graph depicting SIB (Severe Impairment Battery) change from baseline with mean ± SE over 6 months of drug treatment. It compares donepezil hydrochloride 10 mg/day against placebo, showing clinical improvement for donepezil and clinical decline for placebo across the timeline.*

FDA Label Image

Fig-6 (Memantine Donepezil Er Fig 6)

A cumulative percentage of patients graph comparing donepezil hydrochloride 10 mg/day versus placebo based on SIB change from baseline. The x-axis shows SIB change from baseline ranging from +30 to -75, and the y-axis shows cumulative percentage of patients from 0% to 100%. Donepezil is represented by filled circles, and placebo by open squares, indicating a higher cumulative percentage of patients with improvement for donepezil.*

FDA Label Image

Fig-7 (Memantine Donepezil Er Fig 7)

A line graph depicting the ADCS-ADL mean change from baseline over 6 months of drug treatment, comparing donepezil hydrochloride 10 mg/day versus placebo. The y-axis represents clinical improvement or decline, while the x-axis shows months of treatment. Donepezil shows less clinical decline compared to placebo over time.*

FDA Label Image

Fig-8 (Memantine Donepezil Er Fig 8)

A cumulative percentage of patients graph comparing donepezil hydrochloride 10 mg/day vs placebo. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients, illustrating the distribution of patient responses between treatment and placebo groups.*

FDA Label Image

Str (Memantine Donepezil Er Memantine Structure)

Chemical structure diagram of the active ingredient Memantine, showing molecular connectivity and key functional groups including amine hydrochloride and methyl and chlorine substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.